Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City

Rhea-AI Summary

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) announced its participation in the Benzinga Cannabis Capital Conference on October 14-15, 2021, in New York City. The management will present on October 15 at 3:25 p.m. Eastern Time and will engage in one-on-one meetings with investors throughout the event. Anebulo is focused on developing innovative treatments for acute cannabinoid intoxication and substance addiction, with its lead candidate, ANEB-001, demonstrating positive results in clinical trials. Investors can register for the event here.

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced that management will be participating in the Benzinga Cannabis Capital Conference being held October 14 -15, 2021 in person at the Marriott Marquis in New York City and virtually. Management will deliver a company presentation on October 15^th at 3:25 p.m. Eastern Time and will be available for in-person one-on-one meetings with investors throughout the day. Investors can register for the event here and view the live presentation here.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism. For further information about Anebulo, please visit www.anebulo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005012/en/

Anebulo Pharmaceuticals, Inc.

Rex Merchant

Chief Financial Officer

(512) 598-0931

IR@anebulo.com

LHA Investor Relations

Yvonne Briggs

(310) 691-7100

ybriggs@lhai.com

Source: Anebulo Pharmaceuticals, Inc.

FAQ

What will Anebulo Pharmaceuticals present at the Benzinga Cannabis Capital Conference?

Anebulo Pharmaceuticals will present on its lead product candidate, ANEB-001, which aims to reverse the effects of acute cannabinoid intoxication.

When is Anebulo Pharmaceuticals' presentation at the conference?

Anebulo's presentation is scheduled for October 15, 2021, at 3:25 p.m. Eastern Time.

Where is the Benzinga Cannabis Capital Conference being held?

The conference will take place at the Marriott Marquis in New York City.

How can investors register for the Benzinga Cannabis Capital Conference?

Investors can register for the event through the Benzinga website.

What is ANEB-001 developed by Anebulo Pharmaceuticals?

ANEB-001 is a treatment intended to rapidly reverse acute cannabinoid intoxication, showing promising results in clinical trials.